Welcome to our dedicated page for Oncolytics Biotech news (Ticker: ONCY), a resource for investors and traders seeking the latest updates and insights on Oncolytics Biotech stock.
Oncolytics Biotech develops pelareorep, an investigational systemically delivered immunotherapy for cancer that has been shown to activate innate immune-sensing pathways. Company news centers on pelareorep clinical and translational data, FDA interactions, and study activity across gastrointestinal and other solid tumor indications, including metastatic colorectal cancer, squamous cell anal carcinoma, pancreatic cancer, and breast cancer.
Recurring updates also cover the company's registration-focused development priorities, Fast Track Designation for pelareorep-based treatment in second-line KRAS-mutant microsatellite-stable metastatic colorectal cancer, scientific meeting presentations, financing arrangements, and its completed change of jurisdiction to Nevada while ONCY common stock continues to trade on Nasdaq.
Oncolytics Biotech announced the first patient dosing in the phase 2 BRACELET-1 study for HR+/HER2- metastatic breast cancer, under a co-development agreement with Merck KGaA and Pfizer. The study evaluates combination therapies with pelareorep and aims to validate T cell clonality as a biomarker for treatment response. The prior phase 2 trial showed promising results, indicating a near doubling of overall survival. The study will involve 45 patients and will assess safety, tolerability, and efficacy, with results potentially impacting future cancer treatment protocols.
Oncolytics Biotech has initiated an at-the-market (ATM) equity offering sales agreement with Canaccord Genuity, enabling it to raise up to $40 million over 25 months. The ATM provides flexibility to sell common shares at market prices, enhancing the company’s financial positioning for ongoing development and clinical trials of its immuno-oncolytic virus, pelareorep. This strategy may strengthen Oncolytics’ capacity to negotiate future business agreements. The prospectus for this offering has been filed with the appropriate securities commissions.